Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Immatics N.V. (IMTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
08/17/2023 6-K Quarterly results
Docs: "6-K",
"Immatics N.V. interim report for the three and six-month periods ended June 30, 2023",
"Immatics Announces Second Quarter 2023 Financial Results and Business Update",
"Corporate presentation"
08/16/2023 SC 13G ATHOS KG reports a 6.4% stake in IMMATICS N.V.
08/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors · TCER ® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic · Patient enrollment for IMA402 Phase 1/2 trial underway · The trial will evaluate safety, tolerability, and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors · First clinical data expected in 2024 Tuebingen, Germany and Houston, Texas, August 10, 2023 – Immatics N.V. , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the initiation of a Phase 1/2 clinical trial with its proprietary Bispecific T ..."
07/24/2023 6-K Quarterly results
05/26/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Convening Notice for the Annual General Meeting",
"Agenda for the Annual General Meeting",
"Proxy Card"
05/16/2023 6-K Quarterly results
Docs: "6-K",
"Immatics N.V. interim report for the three-month period ended March 31, 2023",
"Immatics Announces First Quarter 2023 Financial Results and Business Update"
05/02/2023 6-K Quarterly results
05/01/2023 6-K Quarterly results
03/22/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/21/2023 6-K Quarterly results
03/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 4.9% stake in IMMATICS N.V.
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 6.8% stake in Immatics N.V.
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Presentation",
"Presentation"
11/17/2022 6-K Quarterly results
11/10/2022 6-K Quarterly results
10/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Presentation",
"Presentation"
10/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Underwriting Agreement, between Immatics N.V. and Jefferies LLC, Jefferies GmbH and SVB Securities LLC, as representatives of the several underwriters",
"Opinion of NautaDutilh N.V",
"Immatics Announces $110 Million Underwritten Offering of Ordinary Shares Houston, Texas and Tuebingen, Germany, October 10, 2022 – Immatics N.V. , a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an underwritten public offering, 10,905,000 of its ordinary shares at a price of $10.09 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $110 million. The offering is expected to close on October 12, 2022, subject to customary closing conditions. The offering included participation from investors including Armistice Capital Master Fund Ltd., Dellora Investments, EcoR1 ..."
10/11/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/11/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/11/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Immatics Reports Interim Clinical Data Update on ACTengine IMA203 TCR-T Monotherapy Targeting PRAME",
"Presentation"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology Congress 2022"
08/23/2022 6-K Quarterly results
08/09/2022 6-K Quarterly results
06/30/2022 6-K Quarterly results
06/24/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/14/2022 6-K Quarterly results
06/13/2022 6-K Quarterly results
06/07/2022 6-K Quarterly results
06/02/2022 6-K Quarterly results
06/02/2022 6-K Quarterly results
05/27/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy